Vitamin D/Calcium Polyp Prevention Study

Colorectal Cancer Clinical Trial

Official title:

Vitamin D/Calcium Polyp Prevention Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00153816
• Other study ID #: 5R01CA098286-03
• Secondary ID: 5R01CA098286-10
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: September 7, 2005
• Last updated: February 6, 2017
• Start date: July 2004
• Est. completion date: June 2016

Study information

• Verified date: February 2017
• Source: Dartmouth-Hitchcock Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Extensive experimental and observational data suggest that intake of calcium and of vitamin D exert protective effects on colorectal neoplasia. Building on their previous work, the investigators will investigate the chemopreventive effect of vitamin D in the large bowel, to study whether calcium with vitamin D is more effective than calcium alone, and to confirm their positive finding regarding calcium. The goal of this study is the development of chemopreventive combinations that will reduce risk of colorectal neoplasia sufficiently to permit the lengthening of surveillance intervals in most patients and to clarify important issues regarding the mechanisms of colorectal carcinogenesis and chemoprevention.

Description:

This study is a double-blind, placebo-controlled trial of vitamin D and/or calcium supplementation for the prevention of large bowel adenomas. Subjects will be recruited from 11 Study Centers in North America. Eligible subjects will have had at least one large bowel adenoma removed in the 4 months prior to study entry and no remaining polyps in the bowel after complete colonoscopic examination. Participants will be randomized in a partial 2 x 2 factorial design to vitamin D (1000 IU/day), calcium carbonate (1200 mg elemental calcium/day), both agents, or placebo only (Full Factorial randomization). Women who decline to forego calcium supplementation will be randomized only to calcium alone or to calcium plus vitamin D (Two Arm randomization). Randomization will be stratified by gender, study center of recruitment, and anticipated follow-up interval (see below), and will be conducted separately for female subjects randomized only to vitamin D. We anticipate enrolling up to 3000 participants to reach a total of up to 2400 randomized subjects. As safety measures, blood levels of calcium, creatinine, and 25-(OH)-vitamin D will be obtained at baseline and 1 year after randomization, as well as 3 years after randomization for subjects with a 5-year surveillance cycle. Every six months after randomization subjects will complete a questionnaire regarding compliance with study agents, use of medications and vitamin/mineral supplements, illnesses, hospitalizations, and dietary intake of calcium and vitamin D. The primary endpoint of the study will be new adenomas detected on follow-up colonoscopy. These examinations are scheduled to occur either 3 years or 5 years after the qualifying examination, depending on the follow-up interval recommended by each patient's endoscopist. Some patients may, for medical reasons, have a colonoscopy at a time other than 3 or 5 years after the qualifying examination. Information from these exams will be included in analyses where appropriate. In the primary analyses, the occurrence of new adenomas in the interval between randomization and the follow-up exam will be compared between subjects randomized to vitamin D (with or without calcium) versus those randomized to no vitamin D (with or without calcium), between subjects randomized to calcium (with or without vitamin D) versus those randomized to no calcium (with or without vitamin D; excluding women electing to receive calcium who therefore cannot participate in the calcium component of the study), and between those randomized to calcium plus vitamin D versus those randomized to calcium alone. In secondary analyses, we will examine the impact of baseline vitamin D levels and vitamin D receptor (VDR) polymorphisms on the vitamin D effects. Effects on advanced adenomas will also be assessed as a secondary outcome. Participants will be invited to participate in an optional Observational Follow Up phase of the study that will begin following the end of treatment. In this phase of the study, subjects will continue to be followed on an observational basis (no study treatment) with annual questionnaires until the time of a subsequent colonoscopy that is at least three years from the follow up colonoscopy at which study treatment was ended. We will examine the occurrence of new adenomas in the interval between the colonoscopy exam at the end of study treatment and the exam at the end of observational follow up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2813
• Est. completion date: June 2016
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• One or more histologically verified neoplastic polyp (adenoma) that is at least 2 mm in size removed from the large bowel with the entire large bowel examined by colonoscopy and documented to be free of further polyps or areas suspicious for neoplasia within 120 days of study entry

• Anticipated colonoscopic follow-up three years or five years after the qualifying colonoscopy

• Age between 45 and 75 years at enrollment

• (Women)Agreement to avoid pregnancy (i.e., use of standard contraception)

• Willingness to forego calcium supplementation (including multivitamins containing calcium) or, for women only, option of taking calcium supplementation of 1200 mg/daily (contained in the study pills)

• Willingness to forego vitamin D supplementation (including multivitamins containing vitamin D)

• Agreement to daily dietary intake of the equivalent of not more than 1200 mg calcium

• Agreement to daily dietary intake of the equivalent of not more than 400 IU vitamin D

• Blood calcium level within normal range

• Blood creatinine level not to exceed 20% above upper limit of normal

• Serum 25-(OH)-vitamin D within lower limit of normal to 70 ng/ml

• Ability and willingness to follow the study protocol, as indicated by provision of informed consent to participate

• Good general health, with no severely debilitating diseases or active malignancy that might compromise the patient's ability to complete the study

Exclusion Criteria:

General exclusionary criteria:

• Participation in another colorectal (bowel) study (intervention study) in the past 5 years

• Current participation in any other clinical trial (intervention study)

• Pregnancy or lactation

• A diagnosis of narcotic or alcohol dependence in the past 5 years

• A diagnosis of dementia (e.g. Alzheimer's) in the past 5 years

• A diagnosis of a significant psychiatric disability (e.g. Schizophrenia, refractory bipolar disorder, current severe depression) in the past 5 years

Exclusions due to derangement of calcium metabolism or indications /contraindications to study agents:

• Any diagnosis of kidney stones

• A diagnosis of granulomatous diseases, e.g. sarcoidosis, active chronic fungal or mycobacterial infections (tuberculosis, histoplasmosis, coccidioidomycosis, blastomycosis), berylliosis, Wegener's granulomatosis in the past 5 years

• A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism in the past 5 years

• A diagnosis of severe kidney disease, e.g. chronic renal failure in the past 5 years

• A diagnosis of unexplained hypercalcemia in the past 5 years

• Any Diagnosis of osteoporosis with physician recommendation for treatment of low bone mass

• A diagnosis of two or more low trauma fractures in the past 5 years

• A diagnosis of a medical condition requiring treatment with vitamin D (e.g. osteomalacia) in the past 5 years

Exclusions due to intestinal or bowel problems:

• Any diagnosis of invasive carcinoma of the large bowel (even if confined to a polyp)

• Any diagnosis of familial colorectal cancer syndromes, e.g. Familial Adenomatous Polyposis (FAP) (including Gardner syndrome, Turcot's syndrome), Hereditary Nonpolyposis Colorectal Cancer (HNPCC), Hamartomatous Polyposis syndromes (including Peutz-Jeghers or Familial Juvenile Polyposis)

• Any diagnosis of inflammatory bowel disease, e.g. Crohn's Disease, Ulcerative Colitis

• A diagnosis of chronic intestinal malabsorption syndromes, e.g. celiac sprue, bacterial overgrowth, chronic pancreatitis, pancreatic insufficiency in the past 5 years

• Any large bowel resection

Exclusions due to poor health:

• A diagnosis of malignancy, other than non-melanoma skin cancer in the past 5 years

• A diagnosis of severe lung disease - class 3 or 4 (e.g. chronic obstructive pulmonary disease or emphysema requiring oxygen) in the past 5 years

• A diagnosis of severe heart disease: cardiovascular disease functional class 3 or 4 in the past 5 years

• Any diagnosis of severe liver disease, e.g. cirrhosis

Exclusions due to shipping regulations:

• Any current/past HIV positive diagnosis

• Active hepatitis B, defined as : Hep B surface antigen positive

• Active hepatitis C, defined as : measurable hepatitis C RNA

Drug exclusions:

• Use of chronic oral corticosteroid therapy in the past 5 years

• Use of lithium in the past 5 years

• Use of phenytoin's in the past 5 years

• Use of quinidine in the past 5 years

• Use of therapeutic vitamin D in the past 5 years

Related Conditions & MeSH terms

• Adenoma
• Adenomas
• Colorectal Cancer
• Colorectal Neoplasms
• Polyps

Intervention

Drug:
• Calcium Carbonate
3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
• Vitamin D3
1000 IU/daily; two tablets per day; 500 IU per tablet
• placebo
placebo; two tablets per day

Locations

Country	Name	City	State
Puerto Rico	University of Puerto Rico	San Juan
United States	Emory University	Atlanta	Georgia
United States	University of North Carolina	Chapel Hill	North Carolina
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	University of South Carolina	Columbia	South Carolina
United States	University of Colorado	Denver	Colorado
United States	University of Texas	Houston	Texas
United States	University of Iowa	Iowa City	Iowa
United States	Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire
United States	University of Southern California	Los Angeles	California
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Dartmouth-Hitchcock Medical Center	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Colorectal Adenomas		1 to 10 years
Secondary	Advanced Colorectal Lesions	Includes: adenomas >=1 cm, adenomas with high grade dysplasia, adenomas with villous features, or cancer.	1 to 10 years